Clinical Trial

A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and tolerability of HRS-7058 combined with antitumor drugs in subjects with solid tumors, and to determine the recommended dosage for Phase II. Evaluate the objective response rate of HRS-7058 in combination with anti-tumor drugs in subjects with solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-13; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2025-08-11
Trial Details
NCT Number NCT07032077
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Solid Tumors
Enrollment 100 participants
Start Date 2025-07-09
Primary Completion 2027-06 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-20